Related Experiment Video
Updated: Jun 23, 2026
10:02
Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
Current therapeutic options for Alzheimer's disease
1Department of Neurology, Hospital Santa Creu i Sant Pau, Avda. San Antoni M feminine Claret 167, Barcelona 08025, Spain.
Current Genomics
|May 6, 2009
Summary
Alzheimer's disease (AD) treatments focus on acetylcholinesterase inhibitors (AChEIs) and memantine for symptomatic relief. Future neuroprotective drugs may slow AD progression.
Area of Science:
- Neurodegenerative diseases
- Gerontology
- Pharmacology
Background:
- Alzheimer's disease (AD) is a prevalent neurodegenerative disorder, increasing with life expectancy.
- Current AD therapies are based on the cholinergic hypothesis, using acetylcholinesterase inhibitors (AChEIs).
- Memantine, an NMDA antagonist, offers an additional therapeutic option, safely combined with AChEIs.
Purpose of the Study:
- To review current Alzheimer's disease (AD) treatments.
- To discuss the role of acetylcholinesterase inhibitors (AChEIs) and memantine.
- To explore emerging neuroprotective drugs for AD.
Main Methods:
- Review of existing clinical trials and therapeutic strategies for AD.
- Analysis of the cholinergic hypothesis and NMDA antagonism in AD treatment.
- Examination of ongoing research into novel neuroprotective agents for AD.
Main Results:
- Acetylcholinesterase inhibitors (AChEIs) provide modest symptomatic benefits for AD.
- Memantine, when combined with AChEIs, offers additional symptomatic improvement.
- Significant advancements in understanding AD pathogenesis are driving the development of new therapies.
Conclusions:
- Current AD pharmacotherapy focuses on symptomatic management.
- Emerging neuroprotective drugs show promise for slowing or preventing AD progression.
- Continued research into AD pathogenesis is crucial for developing effective disease-modifying treatments.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...